Abstract
We measured soluble CD44 (sCD44) by enzyme-linked immunosorbent assay in 216 patients with non-Hodgkin's lymphoma (NHL). The sCD44 level was significantly elevated in patients with NHL. A sCD44 level of > or =500 ng/ml showed a significantly decreased overall survival (OS) rate and progression free survival (PFS) rate. In the high-intermediate+high risk group (international prognostic index (IPI)), both the OS rate and the PFS rate were significantly decreased when the sCD44 level was > or =1000 ng/ml. Moreover, the results of a multivariate analysis showed that the five IPI prognostic factors and the sCD44 level were independent prognostic factors, thus suggesting that sCD44 levels could be a useful prognostic marker for aggressive lymphoma
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antigens, CD / blood
-
Biomarkers, Tumor / blood*
-
Disease Progression
-
Disease-Free Survival
-
Female
-
Humans
-
Hyaluronan Receptors / blood*
-
Lymphoma, B-Cell / blood
-
Lymphoma, B-Cell / mortality
-
Lymphoma, B-Cell / pathology
-
Lymphoma, B-Cell, Marginal Zone / blood
-
Lymphoma, B-Cell, Marginal Zone / mortality
-
Lymphoma, B-Cell, Marginal Zone / pathology
-
Lymphoma, Non-Hodgkin / blood*
-
Lymphoma, Non-Hodgkin / classification
-
Lymphoma, Non-Hodgkin / mortality*
-
Lymphoma, Non-Hodgkin / pathology
-
Lymphoma, T-Cell / blood
-
Lymphoma, T-Cell / mortality
-
Lymphoma, T-Cell / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Predictive Value of Tests
-
Prognosis
-
Reference Values
-
Retrospective Studies
-
Survival Rate
-
Time Factors
Substances
-
Antigens, CD
-
Biomarkers, Tumor
-
Hyaluronan Receptors